Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.71 USD

28.71
28,634,708

-0.17 (-0.59%)

Updated Aug 15, 2024 04:01 PM ET

Pre-Market: $28.64 -0.07 (-0.24%) 8:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II

The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.

Zacks Market Edge Highlights: SHOP, TWLO, PYPL, PFE and PINS

SHOP, TWLO, PYPL, PFE and PINS have been highlighted in this Market Edge article.

Why Is Pfizer (PFE) Down 1.4% Since Last Earnings Report?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer

AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.

Tracey Ryniec headshot

Loser Stocks: Buy More, Hold or Sell?

Did you buy at the pandemic highs and now your stock is in the red? What to do now.

Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use

Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as IBD Market Gains Traction

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study

Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why

Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.

GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.

Novo Nordisk (NVO) to Expand Manufacturing Site in France

Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand

Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Kinjel Shah headshot

Pfizer's (PFE) New Products May Drive Long-Term Sales Growth

Though Pfizer's (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.

The Zacks Analyst Blog Highlights Meta Platforms, Walmart, Pfizer, Intel and Ecolab

The Zacks Analyst Blog Highlights Meta Platforms, Walmart, Pfizer, Intel and Ecolab

Sheraz Mian headshot

Top Analyst Reports for Meta Platforms, Walmart & Pfizer

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Walmart Inc. (WMT) and Pfizer Inc. (PFE).

AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate

To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.

Zacks Earnings Trends Highlights: Pfizer, Eli Lilly, General Motors and Tesla

Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.

Sheraz Mian headshot

Earnings Estimates Come Under Pressure

While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.

Sheraz Mian headshot

Earnings Estimates Come Under Pressure

While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump

Pfizer (PFE) reports mixed third-quarter 2023 results. It re-affirms its 2023 sales and earnings guidance provided earlier this month.

Markets Wait for Fed's FOMC Meeting Decisions

Markets Wait for Fed's FOMC Meeting Decisions.

Mark Vickery headshot

UAW Wins; CAT & PFE Beat, Fall in Pre-Market

This morning, a muted version of yesterday's bull market continues: the Dow is +2 points, and the S&P 500 and the Nasdaq are +6.